Multiple Myeloma: all 3,712 studies
Page 1 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of ElranatamabNot yet recruitingNCT07891871
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingNCT07887984Phase 2/3
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07887672Phase 3
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingNCT07881835Phase 4
- Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain AmyloidosisNot yet recruitingNCT07874334Phase 1
- Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)Not yet recruitingNCT07871747Phase 1
- Serum Soluble BCMA as a Non-Invasive Marker in Multiple MyelomaNot yet recruitingNCT07855718
- Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)RecruitingNCT07851493
- SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersRecruitingNCT07850284
- Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell MobilizationNot yet recruitingNCT07848672Phase 2/3
- Restrictive Versus Standard Antibiotic Treatment During CAR-T TherapyNot yet recruitingNCT07842198Phase 2
- Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F InjectionNot yet recruitingNCT07833046
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 1
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07828522Phase 2
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingNCT07825064Phase 2
- CBC-Based Inflammatory Indices in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07823959
- HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingNCT07811986Phase 2
- Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaNot yet recruitingNCT07789522Phase 2
- Musculoskeletal Ultrasound in Patients With Hematologic MalignanciesNot yet recruitingNCT07785505
- MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple MyelomaNot yet recruitingNCT07783607Not applicable
- CD38 Targeted -PET/ CT for Multiple MyelomaRecruitingNCT07782944Not applicable
- Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07777406
- Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)Not yet recruitingNCT07776964Not applicable
- BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple MyelomaNot yet recruitingNCT07771361Phase 2
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingNCT07764978Phase 3
- A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingNCT07764861Phase 2
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruitingNCT07763054
- A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaRecruitingNCT07760454Phase 1/2
- Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple MyelomaNot yet recruitingNCT07759102Phase 1
- Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07757412Phase 2
- Development and Dissemination of Exercise Prescription and Intervention for Cancer PopulationsRecruitingNCT07751783Not applicable
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
- Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"Not yet recruitingNCT07746232
- A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of CareNot yet recruitingNCT07742527Phase 1
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)RecruitingNCT07742215Phase 3
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingNCT07740486Phase 3
- Neurocognitive Trajectories After BCMA CAR-TRecruitingNCT07740317
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingNCT07735637Phase 3
- A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07735546Phase 1
- Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma CellsNot yet recruitingNCT07732712Phase 2/3
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07728188Phase 3
- Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)Not yet recruitingNCT07727668Early Phase 1
- A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07726160Phase 1
- Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaNot yet recruitingNCT07725406Phase 1
- Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion SystemNot yet recruitingNCT07721350Not applicable
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingNCT07720843Phase 1
- In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaRecruitingNCT07715630Phase 1
- INfections in Patients Treated With CAR-TNot yet recruitingNCT07713511
- FAPI PET Imaging - An Exploratory StudyNot yet recruitingNCT07705074Phase 1/2
- Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07695740Phase 2
- Monitoring MRD in Multiple Myeloma in Serum by Mass SpectrometryNot yet recruitingNCT07691034
- CAR-T in Relapsed/Refractory Multiple MyelomaRecruitingNCT07689058Phase 2
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingNCT07687004Phase 1/2
- Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA FragmentomicsNot yet recruitingNCT07684274
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07681596Phase 1/2
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic MalignanciesNot yet recruitingNCT07679919Phase 1
- Immune Fitness in Older Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT07674498Not applicable
- GMMG-HD11/DSMM XXI/64007957MMY3010Not yet recruitingNCT07671287Phase 3
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07667868Phase 1
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingNCT07665450Phase 3
- Delayed Toxicities Post-CAR-TRecruitingNCT07665307
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253
- GPRC5D Targeted PET/CT Imaging in Plasma Cell DisordersRecruitingNCT07660939Phase 1
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingNCT07657312Phase 2
- A Clinical Study of SHR-5421 in Patients With Multiple MyelomaRecruitingNCT07652281Phase 1
- Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition InterventionRecruitingNCT07649681Not applicable
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
- CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyNot yet recruitingNCT07648459Phase 2
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 3
- PET-Enabled Dual-Energy CT in Multiple MyelomaNot yet recruitingNCT07646873Not applicable
- Digital Support for Multiple Myeloma Quality of LifeRecruitingNCT07642362Not applicable
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).RecruitingNCT07638683Phase 2
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07637578Phase 2
- Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods StudyNot yet recruitingNCT07634263
- Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07628595Early Phase 1
- Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine ImagingNot yet recruitingNCT07624760Not applicable
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingNCT07624513Phase 3
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Phase 3
- Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Phase 1
- Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07614360Phase 2
- A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaNot yet recruitingNCT07612787Phase 1/2
- Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced MyelomaNot yet recruitingNCT07611149Phase 1
- Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)RecruitingNCT07609940Phase 4
- A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingNCT07609706Phase 1
- Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.RecruitingNCT07609576
- A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin LymphomaRecruitingNCT07609030Not applicable
- Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNot yet recruitingNCT07601100Phase 1/2
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
- A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT07589634Phase 2
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Phase 2
- A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaRecruitingNCT07582432Phase 3
- MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease HeterogeneityRecruitingNCT07582354
- Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaRecruitingNCT07581704Phase 1
- A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07579234Phase 3
- Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.RecruitingNCT07577206Early Phase 1
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Phase 3
- Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSNot yet recruitingNCT07567014Phase 2
- BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple MyelomaRecruitingNCT07564219Not applicable
- Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in ItalyNot yet recruitingNCT07564128